Migraine Drugs Market

1. Executive Summary
    1.1. Key Market Insights

2. Introduction
    2.1. Study Objectives
    2.2. Market Definition
           2.2.1. Market Covered
           2.2.2. Regional Coverage
           2.2.3. Study Years & Currency
    2.3. Market Stakeholders
    2.4. Key Questions this Study will Answer
    2.5. GMI Research’s Approach & Methodology
           2.5.1. Research Data
           2.5.2. Primary Data
           2.5.3. Demand Side and Supply Side Analysis
           2.5.4. Market Size Estimation
           2.5.5. Research Assumptions

3. Global Migraine Drugs Market- Overview
    3.1. Introduction
    3.2. Market Segmentation
    3.3. Value Chain Analysis
    3.4. Market Drivers
    3.5. Market Restraints
    3.6. Market Trends

4. Global Migraine Drugs Market Revenue Forecast till 2030

5. Global Migraine Drugs Market by Drug Type Revenue Forecast till 2030
    5.1. Abortive Drugs
    5.2. Preventive Drugs

6. Global Migraine Drugs Market by Route of Administration Revenue Forecast till 2030
    6.1. Oral
    6.2. Injectables
    6.3. Others (Nasal Spray, Transdermal Path, etc.)

7. Global Migraine Drugs Market by End User Revenue Forecast till 2030
    7.1. Hospitals Pharmacies
    7.2. Retail Pharmacies
    7.3. Others

8. Global Migraine Drugs Market by Region Revenue Forecast till 2030
    8.1. North America Migraine Drugs Market Revenue Forecast till 2030
    (Option 1: As a part of the free 25% customization)
           8.1.1. North America Migraine Drugs Market by Drug Type
                     8.1.1.1. Abortive Drugs
                     8.1.1.2. Preventive Drugs
           8.1.2. North America Migraine Drugs Market by Route of Administration
                     8.1.2.1. Oral
                     8.1.2.2. Injectables
                     8.1.2.3. Others (Nasal Spray, Transdermal Path, etc.)
           8.1.3. North America Migraine Drugs Market by End User
                     8.1.3.1. Hospitals Pharmacies
                     8.1.3.2. Retail Pharmacies
                     8.1.3.3. Others
           8.1.4. US Migraine Drugs Market All-Up
           8.1.5. Canada Migraine Drugs Market All-Up
    8.2. Europe Migraine Drugs Market Revenue Forecast till 2030
    (Option 2: As a part of the free 25% customization)
           8.2.1. Europe Migraine Drugs Market by Drug Type
                     8.2.1.1. Abortive Drugs
                     8.2.1.2. Preventive Drugs
           8.2.2. Europe Migraine Drugs Market by Route of Administration
                     8.2.2.1. Oral
                     8.2.2.2. Injectables
                     8.2.2.3. Others (Nasal Spray, Transdermal Path, etc.)
           8.2.3. Europe Migraine Drugs Market by End User
                     8.2.3.1. Hospitals Pharmacies
                     8.2.3.2. Retail Pharmacies
                     8.2.3.3. Others
           8.2.4. UK Migraine Drugs Market All-Up
           8.2.5. Germany Migraine Drugs Market All-Up
           8.2.6. France Migraine Drugs Market All-Up
           8.2.7. Spain Migraine Drugs Market All-Up
           8.2.8. Rest of Europe Migraine Drugs Market All-Up
    8.3. Asia-Pacific Migraine Drugs Market Revenue Forecast till 2030
    (Option 3: As a part of the free 25% customization)
           8.3.1. Asia-Pacific Migraine Drugs Market by Drug Type
                     8.3.1.1. Abortive Drugs
                     8.3.1.2. Preventive Drugs
           8.3.2. Asia-Pacific Migraine Drugs Market by Route of Administration
                     8.3.2.1. Oral
                     8.3.2.2. Injectables
                     8.3.2.3. Others (Nasal Spray, Transdermal Path, etc.)
           8.3.3. Asia-Pacific Migraine Drugs Market by End User
                     8.3.3.1. Hospitals Pharmacies
                     8.3.3.2. Retail Pharmacies
                     8.3.3.3. Others
           8.3.4. China Migraine Drugs Market All-Up
           8.3.5. India Migraine Drugs Market All-Up
           8.3.6. Japan Migraine Drugs Market All-Up
           8.3.7. Rest of APAC Migraine Drugs Market All-Up
    8.4. RoW Migraine Drugs Market Revenue Forecast till 2030
    (Option 4: As a part of the free 25% customization)
           8.4.1. RoW Migraine Drugs Market by Drug Type
                     8.4.1.1. Abortive Drugs
                     8.4.1.2. Preventive Drugs
           8.4.2. RoW Migraine Drugs Market by Route of Administration
                     8.4.2.1. Oral
                     8.4.2.2. Injectables
                     8.4.2.3. Others (Nasal Spray, Transdermal Path, etc.)
           8.4.3. RoW Migraine Drugs Market by End User
                     8.4.3.1. Hospitals Pharmacies
                     8.4.3.2. Retail Pharmacies
                     8.4.3.3. Others
           8.4.4. Brazil Migraine Drugs Market All-Up
           8.4.5. South Africa Migraine Drugs Market All-Up
           8.4.6. Saudi Arabia Migraine Drugs Market All-Up
           8.4.7. UAE Migraine Drugs Market All-Up
           8.4.8. Rest of world (remaining countries of the LAMEA region) Migraine Drugs Market All-Up

9. Competitive Landscape Analysis
    9.1. Porter’s Five Forces Analysis
    9.2. Industry – Competitive Landscape
    9.3. Market Presence (Intensity Mapping)
    9.4. Key Strategic Market Developments

10. Company Profiles (Option 5: Free 25% Customization - Profiles of 5 Additional Companies of your Choice)
    10.1. Abbott Laboratories
           10.1.1. Company Overview
           10.1.2. Key Executives
           10.1.3. Footprint & Employee Strength
           10.1.4. Product Offerings
           10.1.5. Financials
           10.1.6. Key Company Developments
    10.2. Aegis Therapeutics, LLC
           10.2.1. Company Overview
           10.2.2. Key Executives
           10.2.3. Footprint & Employee Strength
           10.2.4. Product Offerings
           10.2.5. Financials
           10.2.6. Key Company Developments
    10.3. Aerial Biopharma LLC
           10.3.1. Company Overview
           10.3.2. Key Executives
           10.3.3. Footprint & Employee Strength
           10.3.4. Product Offerings
           10.3.5. Financials
           10.3.6. Key Company Developments
    10.4. Alder Biopharmaceuticals Inc.,
           10.4.1. Company Overview
           10.4.2. Key Executives
           10.4.3. Footprint & Employee Strength
           10.4.4. Product Offerings
           10.4.5. Financials
           10.4.6. Key Company Developments
    10.5. Amgen Inc Lucibel SA
           10.5.1. Company Overview
           10.5.2. Key Executives
           10.5.3. Footprint & Employee Strength
           10.5.4. Product Offerings
           10.5.5. Financials
           10.5.6. Key Company Developments
    10.6. Astellas Pharma.
           10.6.1. Company Overview
           10.6.2. Key Executives
           10.6.3. Footprint & Employee Strength
           10.6.4. Product Offerings
           10.6.5. Financials
           10.6.6. Key Company Developments
    10.7. AstraZeneca Velmenni OÜ
           10.7.1. Company Overview
           10.7.2. Key Executives
           10.7.3. Footprint & Employee Strength
           10.7.4. Product Offerings
           10.7.5. Financials
           10.7.6. Key Company Developments
    10.8. Johnsons and Johnsons
           10.8.1. Company Overview
           10.8.2. Key Executives
           10.8.3. Footprint & Employee Strength
           10.8.4. Product Offerings
           10.8.5. Financials
           10.8.6. Key Company Developments
    10.9. Eisai Co Ltd
           10.9.1. Company Overview
           10.9.2. Key Executives
           10.9.3. Footprint & Employee Strength
           10.9.4. Product Offerings
           10.9.5. Financials
           10.9.6. Key Company Developments
    10.10. Eli Lily & Co
           10.10.1. Company Overview
           10.10.2. Key Executives
           10.10.3. Footprint & Employee Strength
           10.10.4. Product Offerings
           10.10.5. Financials
           10.10.6. Key Company Developments

11. About GMI Research

*Details on Financials might not be available in case of unlisted/private companies.
*The list of companies is based on preliminary research in this report, the companies in the final report may change based on research findings.